Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

Author： Andersen Jørn   Kamby Claus   Ejlertsen Bent   Cold Søren   Ewertz Marianne   Jacobsen Erik   Philip Preben   Møller Knud   Jensen Disa   Møller Susanne  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.47, Iss.4, 2008-01, pp. : 718-724

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quality of Life in Postmenopausal Patients with Breast Cancer after Failure of Tamoxifen: Formestane Versus Megestrol Acetate as Second-line Hormonal Treatment

By Bernhard J.   Castiglione-Gertsch M.   Schmitz S.-F.H.   Thurlimann B.   Cavalli F.   Morant R.   Fey M.F.   Bonnefoi H.   Goldhirsch A.   Hurny C.  

European Journal of Cancer, Vol. 35, Iss. 6, 1999-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

Formestane Versus Megestrol Acetate in Postmenopausal Breast Cancer Patients After Failure of Tamoxifen: a Phase III Prospective Randomised Cross Over Trial of Second-line Hormonal Treatment (SAKK 2090)

By Swiss Group for Clinical Cancer Research SAKK   Thurlimann B.   Castiglione M.   Hsu-Schmitz S.F.   Cavalli F.   Bonnefoi H.   Fey M.F.   Morant R.   Lohnert T.   Goldhirsch A.  

European Journal of Cancer, Vol. 33, Iss. 7, 1997-06 ,pp. : 1017-1024

Elsevier

Access to resources Recommend Favorite

A Randomised Phase III Cross-over Study of Tamoxifen Versus Megestrol Acetate in Advanced and Recurrent Breast Cancer

By Stuart N.S.A.   Warwick J.   Blackledge G.R.P.   Spooner D.   Keen C.   Taylor A.R.   Tyrell C.   Webster D.J.T.   Earl H.  

European Journal of Cancer, Vol. 32, Iss. 11, 1996-10 ,pp. : 1888-1892

Elsevier

Access to resources Recommend Favorite

Tamoxifen and megestrol acetate for postmenopausal breast cancer: Diverging effects on liver proteins, androgens, and glucocorticoids

By Löfgren L.   Wallberg B.   Wilking N.   Fornander T.   Rutqvist L.   Carlström K.   Schoultz B.   Schoultz E.  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 309-318

Humana Press, Inc

Access to resources Recommend Favorite

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 135-136

Informa Healthcare

Access to resources Recommend Favorite